In Hypogonadism, Stroke May Be Prevented With Testosterone Replacement Therapy

There has been growing concern that testosterone replacement therapy is associated with adverse cardiovascular outcomes.

Testosterone replacement therapy (TRT) may exhibit aprotective effect against myocardial infarction, stroke, and all-cause mortality in men with secondary hypogonadism. The findings were presented at the 26th Annual Scientific and Clinical Congress of the American Association for Clinical Endocrinologists (AACE), held May 3-7, 2017, in Austin,Texas.

Given that there has been growing concern that TRT may be associated with an increased risk for adverse cardiovascular outcomes or mortality, investigators led by Joyce George, MD, of the Cleveland Clinic in Ohio, conducted a retrospective cohort study using electronic health records from a large healthcare database to examine outcomes.

While “the effect of TRT may vary considerably depending on the etiology of low testosterone, the patient’s age, and whetheror not they have established CV [cardiovascular] disease,” the results suggest TRT may protect some men with hypogonadismfrom cardiovascular events, the investigators concluded.

Add some text